Management of Women With Newly Diagnosed Ovarian Cancer

Seminars in Oncology

Volumn 36, Issue 2, 2009, Pages 91-105

  Krasner, Carolyn ^a   Duska, Linda ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CHROMIUM PHOSPHATE P 32; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; MELPHALAN; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE; TOPOTECAN;

ABDOMINAL RADIOTHERAPY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; INTERMETHOD COMPARISON; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KIDNEY DISEASE; KIDNEY INFECTION; LAPAROSCOPY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PATIENT CARE; PRIORITY JOURNAL; SALVAGE THERAPY; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 62949247617     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.12.001     Document Type: Article

References (103)

1. Jemal A., Siegel R., Ward E., Hoo Y., Xu J., Murray T., et al. Cancer statistics, 2008. Ca Cancer J Clin 58 (2008) 71-96
2. Goff B.A., Matthews B.J., Larson E.H., Holly C., Andrilla A., Wynn M., et al. Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109 (2007) 2031-2042
3. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98 (2006) 172-180
4. Bristow R.E., and Berek J.S. Surgery for ovarian cancer: how to improve survival. Lancet 367 (2006) 1558-1560
5. Vernooij F., Heintz P., Witteveen E., and van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 105 (2007) 801-812
6. Monk B.J., and Disaia P.J. What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States experience and debate. Int J Gynecol Cancer 15 Suppl 3 (2005) 199-205
7. Park J.Y., Kim D.Y., Suh D.S., Kim J.H., Kim Y.M., Kim Y.T., et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecol Oncol 110 (2008) 345-353
8. Barlow T.S., Przybylski M., Schilder J.M., Moore D.H., and Look K.Y. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 16 (2006) 496-500
9. Gilani M.M., Karimi Zarchi M., Ghaemmaghami F., Behtash N., Mousavi A.S., and Ansaripoor S. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 105 (2007) 780-783
10. Zivanovic O., Eisenhauer E.L., Zhou Q., Iasonos A., Sabbatini P., Sonoda Y., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 108 (2008) 287-292
11. Cannistra S.A. Cancer of the ovary. N Engl J Med 351 (2004) 2519-2529
12. Bristow R.E., Eisenhauer E.L., Santillan A., and Chi D.S. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104 (2007) 480-490
13. Hou J.Y., Kelly M.G., Yu H., McAlpine J.N., Azodi M., Rutherford T.J., et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105 (2007) 211-217
14. Kumar L., Hariprasad R., Kumar S., Bhatla N., Thulkar S., Vijayaraghavan S., et al. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery versus upfront surgery followed by chemotherapy (CT) in advanced epithelial ovarian carcinoma (EOC): a prospective randomized study-Interim results (2007) Paper presented at: ASCO Annual Meeting, San Francisco, CA
15. Onda T., Matsumoto K., Shibata T., Sato A., Fukuda H., Konishi I., et al. Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group study JCOG0602. Jpn J Clin Oncol 38 (2008) 74-77
16. Van Gorp T., Amant F., Neven P., Berteloot P., Leunen K., and Vergote I. The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer. Cancer Treat Res 134 (2007) 387-402
17. Sabbatini P., and Spriggs D.R. Consolidation for ovarian cancer in remission. J Clin Oncol 24 (2006) 537-539
18. Hoskins W.J. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 55 (1994) S91-S96
19. Ahmed F.Y., Wiltshaw E., A'Hern R.P., Nicol B., Shepherd J., Blake P., et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 14 (1996) 2968-2975
20. Young R.C., Walton L.A., Ellenberg S.S., Homesley H.D., Wilbanks G.D., Decker D.G., et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322 (1990) 1021-1027
21. Young R.C., Brady M.F., Nieberg R.K., Long H.J., Mayer A.R., Lentz S.S., et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 4350-4355
22. Bolis G., Colombo N., Pecorelli S., Torri V., Marsoni S., Bonazzi C., et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica. Ann Oncol 6 (1995) 887-893
23. Colombo P.E., Mourregot A., Fabbro M., Gutowski M., Saint-Aubert B., Quenet F., et al. Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol 35 (2009) 135-143
24. Vergote I.B., Vergote-De Vos L.N., Abeler V.M., Aas M., Lindegaard M.W., et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 69 (1992) 741-749
25. Thigpen T., Vance R.B., McGuire W.P., Hoskins W.J., and Brady M. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Semin Oncol 22 Suppl 14 (1995) 23-31
26. Trimbos J.B., Parmar M., Vergote I., Guthrie D., Bolis G., Colombo N., et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95 (2003) 105-112
27. Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioni C., Madronal C., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95 (2003) 113-125
28. Bell J., Brady M.F., Young R.C., Lage J., Walker J.L., Look K.Y., et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 102 (2006) 432-439
29. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
30. Eisenkop S.M., Spirtos N.M., and Lin W.C. "Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary. Gynecol Oncol 103 (2006) 329-335
31. Winter W.E., Maxwell G.L., Tian C., Sundborg M.J., Rose G.S., Rose P.G., et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 26 (2008) 83-89
32. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979
33. Naik R., Nordin A., Cross P.A., Hemming D., de Barros Lopes A., and Monaghan J.M. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 78 (2000) 171-175
34. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72 (1999) 278-287
35. Eisenkop S.M., Spirtos N.M., Montag T.W., Nalick R.H., and Wang H.J. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 (1992) 203-209
36. Paulsen T., Kjaerheim K., Kaern J., Tretli S., and Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16 Suppl 1 (2006) 11-17
37. Nelson B.E., Rosenfield A.T., and Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11 (1993) 166-172
38. Dowdy S.C., Mullany S.A., Brandt K.R., Huppert B.J., and Cliby W.A. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma. Cancer 101 (2004) 346-352
39. Byrom J., Widjaja E., Redman C.W., Jones P.W., and Tebby S. Can pre-operative computed tomography predict resectability of ovarian carcinoma at primary laparotomy?. BJOG 109 (2002) 369-375
40. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S., et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25 (2007) 384-389
41. Bristow R.E., Duska L.R., Lambrou N.C., Fishman E.K., O'Neill M.J., Trimble E.L., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89 (2000) 1532-1540
42. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77 (2000) 227-231
43. Gemer O., Segal S., and Kopmar A. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer. Acta Obstet Gynecol Scand 80 (2001) 583-585
44. Gemer O., Lurian M., Gdalevich M., Kaputsian V., Piura E., Schneider D., et al. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer. Eur J Surg Oncol 31 (2005) 1006-1010
45. Cooper B.C., Sood A.K., Davis C.S., Ritchie J.M., Sorosky J.I., Anderson B., et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol 100 (2002) 59-64
46. de Jong D., Eijkemans M.J., Lie Fong S., Gerestein C.G., Kooi G.S., Baalbergen A., et al. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma. Oncology 72 (2007) 293-301
47. Deffieux X., Castaigne D., and Pomel C. Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer. Int J Gynecol Cancer 16 Suppl 1 (2006) 35-40
48. Fagotti A., Ferrandina G., Fanfani F., Ercoli A., Lorusso D., Rossi M., et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13 (2006) 1156-1161
49. Salani R., Axtell A., Gerardi M., Holschneider C., and Bristow R.E. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 108 (2008) 271-275
50. Moore K.N., Reid M.S., Fong D.N., Myers T.K., Landrum L.M., Moxley K.M., et al. Ovarian cancer in the octogenarian: does the paradigm of aggressive cytoreductive surgery and chemotherapy still apply?. Gynecol Oncol 110 (2008) 133-139
51. Aletti G.D., Santillan A., Eisenhauer E.L., Hu J., Aletti G., Podratz K.C., et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 107 (2007) 99-106
52. Geisler J.P., Linnemeier G.C., Thomas A.J., and Manahan K.J. Nutritional assessment using prealbumin as an objective criterion to determine whom should not undergo primary radical cytoreductive surgery for ovarian cancer. Gynecol Oncol 106 (2007) 128-131
53. Alphs H.H., Zahurak M.L., Bristow R.E., and Diaz-Montes T.P. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer. Gynecol Oncol 103 (2006) 1048-1053
54. Omura G.A., Morrow C.P., Blessing J.A., Miller A., Buchsbaum H.J., Homesley H.D., et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer 51 (1983) 783-789
55. Thigpen T., Vance R., Puneky L., and Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55 (1994) S97-S107
56. McGuire W.P., and Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin Oncol 25 (1998) 340-348
57. Chemotherapy in advanced ovarian cancer. an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ 303 (1991) 884-893
58. Alberts D.S., Green S., Hannigan E.V., O'Toole R., Stock-Novack D., Anderson P., et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10 (1992) 706-717
59. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 352 (1998) 1571-1576
60. McGuire W.P., Rowinsky E.K., Rosenshein N.B., Grumbine F.C., Ettinger D.S., Armstrong D.K., et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111 (1989) 273-279
61. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
62. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92 (2000) 699-708
63. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
64. du Bois A., Lück H.J., Meier W., Adams H.P., Möbus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003) 1320-1329
65. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 352 (1998) 1571-1576
66. Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96 (2004) 1682-1691
67. Bookman M.A. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitibine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma (2006) Paper presented at: ASCO Annual Meeting, Atlanta, GA
68. du Bois A., Weber B., Rochon J., Meier W., Goupil A., Olbricht S., et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol 24 (2006) 1127-1135
69. Hakes T.B., Chalas E., Hoskins W.J., Jones W.B., Markman M., Rubin S.C., et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45 (1992) 284-289
70. Markman M., Rowinsky E., Hakes T., Reichman B., Jones W., Lewis J.L., et al. Phase I trial of intraperitoneal Taxol: a Gynecoloic Oncology Group study. J Clin Oncol 10 (1992) 1485-1491
71. Bertelsen K., Jakobsen A., Strøyer J., Nielsen K., Sandberg E., Andersen J.E., et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49 (1993) 30-36
72. De Placido S., Scambia G., Di Vagno G., Naglieri E., Lombardi A.V., Biamonte R., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol 22 (2004) 2635-2642
73. Pfisterer J., Weber B., Reuss A., Kimmig R., du Bois A., Wagner U., et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98 (2006) 1036-1045
74. Frei III E., and Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 69 (1980) 585-594
75. Levin L., and Hryniuk W.M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5 (1987) 756-767
76. Levin L., Simon R., and Hryniuk W. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 85 (1993) 1732-1742
77. Jakobsen A., Bertelsen K., Andersen J.E., Havsteen H., Jakobsen P., Moeller K.A., et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15 (1997) 193-198
78. Bolis G., Scarfone G., Polverino G., Raspagliesi F., Tateo S., Richiardi G., et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 22 (2004) 686-690
79. Rowinsky E.K., Mackey M.K., and Goodman S.N. Meta-analysis of paclitaxel (P) dose-response and dose intensity (DI) in recurrent or refractory ovarian cancer (OC) (meeting abstract no. 970) (1996) Paper presented at: ASCO Annual Meeting, Philadelphia, PA
80. Omura G.A., Brady M.F., Look K.Y., Averette H.E., Delmore J.E., Long H.J., et al. Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study. J Clin Oncol 21 (2003) 2843-2848
81. Dedrick R.L., Myers C.E., Bungay P.M., and DeVita Jr. V.T. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62 (1978) 1-11
82. DeGregorio M.W., Lum B.L., Holleran W.M., Wilbur B.J., and Sikic B.I. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol 18 (1986) 235-238
83. Howell S.B., Pfeifle C.L., Wung W.E., Olshen R.A., Lucas W.E., Yon J.L., et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97 (1982) 845-851
84. Francis P., Rowinsky E., Schneider J., Hakes T., Hoskins W., and Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study. J Clin Oncol 13 (1995) 2961-2967
85. Markman M., Reichman B., Hakes T., Jones W., Lewis J.L., Rubin S., et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 9 (1991) 1801-1805
86. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., and Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 17 (1997) 337-342
87. Tempfer C., Zeisler H., Sliutz G., Haeusler G., Hanzal E., and Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 66 (1997) 27-30
88. Duan Z., Feller A.J., Penson R.T., Chabner B.A., and Seiden M.V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5 (1999) 3445-3453
89. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
90. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
91. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
92. Pfeiffer P., Bennedbaek O., and Bertelsen K. Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer. Gynecol Oncol 36 (1990) 306-311
93. Markman M., Reichman B., Hakes T., Rubin S., Lewis J.L., Jones W., et al. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer. Gynecol Oncol 50 (1993) 100-104
94. Nagao S., Fujiwara K., Ohishi R., Nakanishi Y., Iwasa N., Shimizu M., et al. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer. Int J Gynecol Cancer 18 (2008) 1210-1214
95. van der Burg M.E., van Lent M., Buyse M., Kobierska A., Colombo N., Favalli G., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332 (1995) 629-634
96. Coldman A.J., and Goldie J.H. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 48 (1986) 279-292
97. Santin A.D., Hermonat P.L., Ravaggi A., Cannon M.J., Pecorelli S., and Parham G.P. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 20 (1999) 177-181
98. Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., et al. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 9 (2003) 1361-1369
99. Mesiano S., Ferrara N., and Jaffe R.B. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153 (1998) 1249-1256
100. Burger R.A., Sill M.W., Monk B.J., Greer B.E., and Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 5165-5171
101. Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 26 (2008) 76-82
102. Cannistra S.A., Matulonis U.A., Penson R.T., Hambleton J., Dupont J., Mackey H., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25 (2007) 5180-5186
103. Simpkins F., Belinson J.L., and Rose P.G. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol 107 (2007) 118-123